Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Journal of Cellular and Molecular Medicine|December 14, 2020
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapyJing Pan, Biping Deng, Zhuojun Ling, et al.
Frontiers in Immunology|August 8, 2025
Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphomaZhongqing Zou, Sihan Lai, Hai Yi, et al.
Frontiers in Immunology|September 8, 2025
Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphomaZhongqing Zou, Sihan Lai, Hai Yi, et al.
Respiratory Research|November 1, 2020
Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cellsHuan Liu, Qian Cheng, Dong-Sheng Xu, et al.
Blood Cancer Discovery|July 8, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid MalignanciesRongrong Chen, Haiqiong Zheng, Wenxin Wang, et al.
BMC Cancer|April 12, 2022
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapyLihong An, Yuehui Lin, Biping Deng, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALLYue Tan, Jing Pan, Biping Deng, et al.
Journal for Immunotherapy of Cancer|February 22, 2023
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALLFengmei Song, Yongxian Hu, Yanlei Zhang, et al.
Frontiers in Medicine|January 29, 2026
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrierDanyang Li, Rui Liu, Zhonghua Fu, et al.
American Journal of Hematology|March 16, 2021
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantationShuangyou Liu, Biping Deng, Zhichao Yin, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Journal of Cellular and Molecular Medicine|December 14, 2020
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapyJing Pan, Biping Deng, Zhuojun Ling, et al.
Frontiers in Immunology|August 8, 2025
Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphomaZhongqing Zou, Sihan Lai, Hai Yi, et al.
Frontiers in Immunology|September 8, 2025
Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphomaZhongqing Zou, Sihan Lai, Hai Yi, et al.
Respiratory Research|November 1, 2020
Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cellsHuan Liu, Qian Cheng, Dong-Sheng Xu, et al.
Blood Cancer Discovery|July 8, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid MalignanciesRongrong Chen, Haiqiong Zheng, Wenxin Wang, et al.
BMC Cancer|April 12, 2022
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapyLihong An, Yuehui Lin, Biping Deng, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALLYue Tan, Jing Pan, Biping Deng, et al.
Journal for Immunotherapy of Cancer|February 22, 2023
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALLFengmei Song, Yongxian Hu, Yanlei Zhang, et al.
Frontiers in Medicine|January 29, 2026
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrierDanyang Li, Rui Liu, Zhonghua Fu, et al.
American Journal of Hematology|March 16, 2021
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantationShuangyou Liu, Biping Deng, Zhichao Yin, et al.
Pageof 8